Insight Genetics Pursues Diagnostic for Lung Cancer

Mar 5, 2012, 00:05 AM by Michael Croft

Tennessean | Insight Genetics just signed a key distribution agreement with Qiagen to bring its diagnostic test for a genetic mutation for Anaplastic Lymphoma Kinase (ALK) to market.

March 5, 2012 | Insight Genetics just signed a key distribution agreement with Qiagen to bring its diagnostic test for a genetic mutation for Anaplastic Lymphoma Kinase (ALK) to market. The mutation causes about 5% of lung cancers. CEO Eric Dahlhauser talks about personalized medicine, NCI, and the company's growth plans. Tennesseean.